Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 300.03k | 534.36% |
| Gross profit | -2.66m | 20.85% |
| Net profit | -3.96m | 44.04% |
| EBITDA | -3.84m | 25.90% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.8m |
Number of shares | 5.15m |
52-week high/low | €2.00 - €0.30 |
| Dividends | No |
Beta | 0.18 |
P/E ratio | -0.44 |
PEG ratio | 0.00 |
P/B ratio | -0.39 |
P/S ratio | 6.00 |
Company profile
Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.
| Name | Medesis Pharma SA |
| CEO | Jean-Claude Maurel MHB |
| Headquarters | Montpellier,
France |
| Website | |
| IPO | 12/02/2021 |
| Employees | 10 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | ALMDP.PA |
Frankfurt | 76D.F |
Paris | ALMDP.PA |
München | 76D.MU |
